ストックスクリーナーアプリを入手
5.42
5.41%
-0.31
アフターアワーズ：
5.40
-0.02
-0.37%
前日終値:
$5.73
開ける：
$5.74
24時間の取引高:
98,166
Relative Volume:
1.85
時価総額：
$12.67M
収益：
-
当期純損益:
$-14.39M
株価収益率:
-0.6763
EPS:
-8.0144
ネットキャッシュフロー:
$-11.83M
1週間 パフォーマンス:
-25.14%
1か月 パフォーマンス:
-37.20%
6か月 パフォーマンス:
-61.83%
1年 パフォーマンス:
-72.21%
1日の値動き範囲:
$4.94
$5.74
1週間の範囲:
$4.94
$7.22
52週間の値動き範囲:
$4.91
$19.84
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Compare CVKD vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
5.42 | 13.40M | 0 | -14.39M | -11.83M | -8.0144 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-18 | 開始されました | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc (CVKD) 最新ニュース
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Technical Reactions to CVKD Trends in Macro Strategies - Stock Traders Daily
Fed Meeting: What is Cadrenal Therapeutics Incs valuation compared to sectorGold Moves & Fast Moving Trade Plans - baoquankhu1.vn
Buy Signal: Will Cadrenal Therapeutics Inc outperform its industry peersPortfolio Performance Summary & AI Forecasted Stock Moves - baoquankhu1.vn
OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Trading Action: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum - Defense World
CVKD SEC FilingsCadrenal Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Cadrenal Therapeutics, Inc. (CVKD) stock: surges on breakthrough 12-LOX diabetes research - parameter.io
Cadrenal Therapeutics Inc. (CVKD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Trading the Move, Not the Narrative: (CVKD) Edition - Stock Traders Daily
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Sahm
CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data - TradingView
CVKD: CAD-1005 advances to phase III for HIT, targeting a major unmet need with strong regulatory support - TradingView
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease - TipRanks
Cadrenal Therapeutics (CVKD) spotlights CAD-1005 12-LOX data in obesity, diabetes and HIT - Stock Titan
Trend Recap: What is Cadrenal Therapeutics Incs valuation compared to sector2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Cadrenal Therapeutics Inc expected to post a loss of $1.16 a shareEarnings Preview - TradingView
CVKD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday - Defense World
CVKDCadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - ADVFN Ltd
Cadrenal schedules FDA meeting for HIT drug CAD-1005 - Investing.com India
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewswire
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - Defense World
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
CVKD Should I Buy - Intellectia AI
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial - Investing.com India
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events - Yahoo Finance
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial By Investing.com - Investing.com Canada
Cadrenal Therapeutics stock surges on Phase 2 trial results - Investing.com South Africa
Cadrenal Therapeutics' recent acquisition makes progress toward phase 3 trial - The Business Journals
Cadrenal Therapeutics stock surges on Phase 2 trial results By Investing.com - Investing.com Nigeria
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005 - TipRanks
Cadrenal Therapeutics Inc recently received approval from the U.S. Food and Drug Administration (FDA) to hold an end-of-Phase II clinical trial meeting. - Bitget
Cadrenal Therapeutics announces phase 2 results for CAD-1005 - marketscreener.com
Cadrenal Therapeutics Reports Over 25% Reduction in Thrombotic Events with CAD-1005 in Phase 2 Trial for Heparin-Induced Thrombocytopenia - Quiver Quantitative
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - Bitget
Cadrenal Therapeutics reports Phase 2: CAD-1005 cuts thrombotic events >25% vs placebo; EOP2 meeting set - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results For CAD-1005 - TradingView
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
Smart Money: What is Cadrenal Therapeutics Incs valuation compared to sector2025 Support & Resistance & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Cadrenal Therapeutics expands at-the-market stock offering capacity - MSN
What is Cadrenal Therapeutics Inc. s revenue forecastJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - mfd.ru
Trading Recap: Can Cadrenal Therapeutics Inc. stock double in the next yearDollar Strength & Daily Growth Stock Investment Tips - mfd.ru
CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT) - Yahoo Finance
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - Intellectia AI
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 22.1% in January - Defense World
Can Cadrenal Therapeutics Inc. weather a recessionJuly 2025 Selloffs & Weekly Chart Analysis and Guides - mfd.ru
Cadrenal Therapeutics Inc (CVKD) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):